Duke Physicians Find Intensive Radiation Therapy Can Save Lives, Improve Quality Of Life For Patients With Head And Neck Cancers

June 18, 1998

DURHAM, N.C. -- People who are diagnosed with invasive cancer of the head and neck are usually given a grim prognosis. Many die within three years of diagnosis.

The standard treatment for advanced head and neck cancer has been to treat patients with surgery and seven weeks of once-daily radiation therapy. But a new study from Duke University Medical Center finds that when patients are treated with a novel combination of intensive, twice-daily radiation therapy and simultaneous chemotherapy, their disease can be controlled much more frequently.

The findings of the phase III clinical trial appear in the June 18 issue of the New England Journal of Medicine. The research was funded in part by the Duke Comprehensive Cancer Center.

"The improvement for these patients was significant enough that this now constitutes our standard of care at Duke," said Dr. David M. Brizel, associate professor of radiation oncology and member of the Duke Comprehensive Cancer Center.

Each year approximately 50,000 people in the United States are diagnosed with cancer of the head or neck, typically the larynx, pharynx, or tongue. Most cases are associated with cigarette or cigar smoking, or chewing tobacco products.

"If the cancer is detected in an early stage, it is very curable with surgery or radiotherapy alone," he said. "But about 70 percent of these cancers are locally advanced, meaning the cancer is large and has invaded surrounding tissues or spread to the lymph nodes in the neck. Most of these patients will die of their disease within three years with conventional treatment. Moreover, surgery is often disfiguring, and patients may have pain and difficulty swallowing from their radiation treatments."

Brizel and his colleagues devised a strategy that involves treating patients with more radiation, but dividing it into smaller doses. Instead of having one treatment per day, all patients had two treatments per day for five to six weeks. At the same time, half of the 116 patients in the study also received cisplatin and 5-fluorouracil, two chemotherapy drugs commonly used to treat head and neck cancer, during the first and sixth weeks of irradiation.

The researchers found the combined treatment was more successful in controlling the cancer and in stopping recurrence of tumors. Sixty-one percent of the combined treatment patients were still disease-free after three years, compared to 41 percent for the intensive radiation therapy alone. However, both groups did much better than the 25 percent to 30 percent survival that would have been expected with standard once-a-day radiation treatment. The researchers found no increased long-term complications from the addition of the chemotherapy to the radiation.

"We are encouraged by these results," Brizel added. "However, it is important to remember that many patients still die from this disease. We are continuing to try to improve our treatment strategies to help more patients live longer, fuller lives."

Dr. Mary Albers, Dr. Samuel Fisher, Dr. Richard Scher, Dr. William Richtsmeier, Vera Hars, Stephen George, Dr. Andrew Huang and Dr. Leonard Prosnitz, all of Duke Comprehensive Cancer Center, also contributed to the study.
-end-


Duke University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.